Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005;26(2-3):233-8.
doi: 10.1385/JMN:26:2-3:233.

Functions of heteromeric association between adenosine and P2Y receptors

Affiliations
Review

Functions of heteromeric association between adenosine and P2Y receptors

Hiroyasu Nakata et al. J Mol Neurosci. 2005.

Abstract

It is now well accepted that G protein-coupled receptors (GPCRs) can be directly associated, as either homo- or hetero-oligomers, to alter their functions. G protein-coupled purinergic receptors, classified as adenosine receptors, and P2Y receptors (ATP receptors) are also found to oligomerize each other to alter their pharmacology. Specifically, adenosine receptor of A1 subtype (A1R) is able to form a heteromeric complex with P2Y receptor of P2Y1 type (P2Y1R) either in heterologously transfected cells or in rat brain tissues, as demonstrated by coimmunoprecipitation or bioluminescence resonance energy transfer methods in addition to double immunocytochemistry. It is shown that the heteromerization between A1R and P2Y1R generates an adenosine receptor with P2Y-like agonistic pharmacology, i.e., a potent P2Y1R agonist, adenosine 5'-O-(2-thiodiphosphate), binds the A1R binding pocket of the A1R/P2Y1R complex and inhibits adenylyl cyclase activity via Gi/o protein. This hetero-oligomerization between adenosine receptor and P2Y receptor might be one of the mechanisms for the adenine nucleotide-mediated inhibition of neurotransmitter release. The oligomerization of purinergic receptors is thus considered as an important regulation system in the central nervous system.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Annu Rev Pharmacol Toxicol. 2002;42:409-35 - PubMed
    1. FEBS Lett. 2002 Jul 17;523(1-3):147-51 - PubMed
    1. Clin Exp Pharmacol Physiol. 1997 Jul;24(7):492-7 - PubMed
    1. Neuron. 2003 Dec 4;40(5):971-82 - PubMed
    1. Naunyn Schmiedebergs Arch Pharmacol. 1992 Aug;346(2):187-96 - PubMed

Publication types

MeSH terms

LinkOut - more resources